Cargando…

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

In Germany, ~8 million patients take angiotensin receptor blockers (ARBs) and 2.25 million of them valsartan. In 2018, contamination of generic ARBs with probable carcinogenic nitrosamines resulted in more than 30 recalls. The impact of such a huge recall has never been explored in Europe. We analyz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rudolph, Ulrike Maria, Enners, Salka, Kieble, Marita, Mahfoud, Felix, Böhm, Michael, Laufs, Ulrich, Schulz, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502678/ https://www.ncbi.nlm.nih.gov/pubmed/33057175 http://dx.doi.org/10.1038/s41371-020-00425-z

Ejemplares similares

Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia
por: Mahfoud, Felix, et al.
Publicado: (2022)

Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
por: Katzmann, Julius L., et al.
Publicado: (2022)

Utilization of drugs with reports on potential efficacy or harm on COVID‐19 before, during, and after the first pandemic wave
por: Enners, Salka, et al.
Publicado: (2021)

Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014–2019
por: Gradl, Gabriele, et al.
Publicado: (2021)

Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare
por: Gillette, Michael, et al.
Publicado: (2020)

Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016
por: Gradl, Gabriele, et al.
Publicado: (2018)

Assessment of the Prescriptions of Systemic Antibiotics in Primary Dental Care in Germany from 2017 to 2021: A Longitudinal Drug Utilization Study
por: Gradl, Gabriele, et al.
Publicado: (2022)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats
por: Jin, Kyubok, et al.
Publicado: (2013)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Bryniarski, Paweł, et al.
Publicado: (2022)

Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk
por: Katzmann, Julius L, et al.
Publicado: (2018)

Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients
por: Mekary, Wissam, et al.
Publicado: (2023)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide
por: Flack, J M
Publicado: (2007)

Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers
por: Ekman, Elisabet, et al.
Publicado: (2010)

Association of mononucleotide polymorphisms of angiotensinogen gene at promoter region with antihypertensive response to angiotensin receptor blockers in hypertensive Chinese
por: Gong, Hong-Tao, et al.
Publicado: (2019)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Ku, Elaine, et al.
Publicado: (2018)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Response surface analyses of antihypertensive effects of angiotensin receptor blockers and amlodipine or hydrochlorothiazide combination therapy in patients with essential hypertension
por: Cho, Minhee, et al.
Publicado: (2023)

Effects of a Step-Therapy Program for Angiotensin Receptor Blockers on Antihypertensive Medication Utilization Patterns and Cost of Drug Therapy
por: Yokoyama, Krista, et al.
Publicado: (2007)

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
por: Hansen, Kerstin, et al.
Publicado: (2015)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

A Comparison of Disease Severity and Outcomes in COVID-19 Cases Taking Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Versus Other Antihypertensive Drugs
por: Abdullah, Muhammad, et al.
Publicado: (2021)

Impact of angiotensin receptor blocker as antihypertensive in assessing mortality in patients of COVID-19: A single tertiary care center study
por: Acharya, Sourya, et al.
Publicado: (2023)

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
por: Baumhäkel, Magnus, et al.
Publicado: (2011)

Assessment of quality and readability of internet-based health information related to commonly prescribed angiotensin receptor blockers
por: Oloidi, Anuoluwapo, et al.
Publicado: (2020)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials
por: Cuspidi, Cesare, et al.
Publicado: (2009)

Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database
por: Bhaskaran, Krishnan, et al.
Publicado: (2012)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
por: Pires de Souza, Gabriel Augusto, et al.
Publicado: (2021)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data
por: Hiroi, Shinzo, et al.
Publicado: (2016)

Herbicidal properties of antihypertensive drugs: calcium channel blockers
por: Abdullah, Hannan Safiyyah Tan Sian Hui, et al.
Publicado: (2021)

Adherence to antihypertensive medication in renal denervation trials: new studies, old problems?
por: Lauder, Lucas, et al.
Publicado: (2023)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nm862jd0v9a61j8k8fke2sr4ij